The use of fructosamine in cystic fibrosis-related diabetes (CFRD) screening

Objective: To determine whether serum fructosamine correlates with glycemic control and clinical outcomes in patients being screened for cystic fibrosis-related diabetes (CFRD). Methods: Fructosamine and percent predicted forced expiratory volume in 1 s (FEV1) were measured in patients undergoing a 2 h oral glucose tolerance test (OGTT) for CFRD screening. Fractional serum fructosamine (FSF) was calculated as fructosamine/total protein. Results: FSF exhibited a positive correlation with 2 h OGTT results (r(2) = 0.3201, p = 0.009), and ROC curve analysis suggested that FSF can identify patients with an abnormal OGTT (AUC = 0.840, p = 0.0002). FSF also exhibited a negative correlation with FEV1 (r(2) = 0.3732, p = 0.035). Patients with FSF >= 3.70 mu mol/g had significantly lower FEV1 (median 47%) compared to those with FSF < 3.70 mu mol/g (median 90%; p = 0.015). Conclusions: FSF correlated with both OGTT results and FEV1, and reliably identified patients with abnormal OGTT results. This simple blood test shows potential as an effective tool in CFRD screening. (C) 2017 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.